SOCIUM Inc. started its operations in September 2017 with a corporate mission,
“Drug discovery for patients with no drug, Drug discovery for patients with ineffective drug.”
“socium” means “Partner” in Latin. SOCIUM committed to being a partner with people that hope to enjoy healthier life.
We will contribute the drug research and development by solving pharma partners’ issues.
By shaping drug discovery process, we will make an effort to discover medicines for patients with no drug.
Furthermore, we will continue to move ahead on providing patients with innovative medicines earlier with pharma partners.
Hiroshi KAWAI, Ph.D.
Board Director CEO
Mitsubishi Tanabe, Mitsubishi Tanabe Holdings America
Led Business Development for 15 years.
2019/10 Director of Socium.
2020/6 Board Director of Socium.
Katsuhisa HORIMOTO, Ph.D.
Board Director CTO, Founder
>130 peer-reviewed papers on computational systems biology, 8 parents of algorithms.
2017/9 CTO, Co-founder of Socium.
2019/4 Invited Researcher of AIST, Visiting Professor of Saitama Medical Univ.
Atsushi USAMI, Ph.D.
Worked at Mitsubishi Research Institute, Inc., in charge of the development of new business strategies and management plans in the life science sector.
Joined University of Tokyo Edge Capital Partners (UTEC) in October 2013. At present, a director and partner in charge of seed/early stage investments and management support.
Also a supporter of the Life Science Innovation Network Japan (LINK-J).
|Company Name||SOCIUM Inc.|
|Office||17-1, Nihonbashi-Kabuto-cho, Chuo-ku, Tokyo 103-0026, Japan|
|Laboratory||AIST Tokyo Waterfront, 2-4-7, Aomi, Koto-ku, Tokyo 135-0064, Japan